Introduction
The thymus is profoundly involved in the pathogenesis of myasthenia gravis (MG).' It is generally known that most, if not all myasthenia patients have pathological changes of their thymic tissue. Specifically, > 70% of all myasthenic thymuses show lymphofollicular hyperplasia, and at least 10% of myasthenic patients have thymic epithelial neoplasia (1) . A causal connection between thymic changes and the development of clinical MG has been suggested by the beneficial therapeutic effects of thymus extirpation. In fact, at least in MG with short duration of symptoms, associated with thymus hyperplasia, thymectomy appears to be one of the most re-warding therapeutic measures (2) (3) (4) (5) . Finally, at least an indirect role of the thymus was indicated by the demonstration of putatively thymus-dependent cellular responses against the nicotinic acetylcholine receptor (AChR) in MG patients (6) (7) (8) .
This clinical experience together with the observation of myogenic inducibility of thymic stem cells in culture (9) led us to postulate that in MG the thymus is the primary site of a pathogenic autoimmune response against the postsynaptic AChR (10, 1 1). We proposed a four-step sequence of intrathymic pathogenesis: (a) myogenic induction of primitive thymic stem cells leading to synthesis and expression of AChR on thymic myoid cells; (b) release of AChR from myoid cells, perhaps due to cell death, and uptake of myoid AChR by thymic antigen presenting cells (e.g., interdigitating cells, IDC) and immunogenic presentation; (c) recognition of immunogenically presented AChR by specific autoreactive T lymphocytes, differentiating within the thymus; (d) emigration of the activated AChR specific T lymphocytes to the peripheral immune system, interaction with AChR specific B cells resulting in the production of pathogenic anti-AChR autoantibodies.
This report supports a central element of the concept of intrathymic generation of MG. We demonstrate that thymus tissues from myasthenic patients indeed regularly contain T lymphocytes which can recognize and react against AChR. There is evidence that AChR specific T cells are more frequent within the thymus than in peripheral compartments of the immune system, e.g., peripheral blood. We furthermore show that these T cells can be isolated and propagated as AChR specific T cell lines and that all the T cell lines recovered express membrane markers of the CD4 T cell subset.
Methods
Patients. All patients were seen in the Department of Neurology (Director, Prof. Dr. H. G. Mertens) ofthe University ofWurzburg, and are participants in a double-blind controlled trial comparing the benefits of longterm immunosuppression of cyclosporin A vs. azathioprine (12) .
Diagnosis of MG was based on clinical examination, amplitude decrement during repetitive EMG stimulation, positive edrophonium and/or curare test. Clinical grading was done according to Osserman (13) . In 9 of 10 patients anti-AChR antibodies were determined (Dr. I. Kalies, Erlangen). Transsternal thymectomy was performed at the Department of Thoracic Surgery of the University of Wurzburg. All patients gave written consent for their specimens to be used for research.
Antigens. A preservative free preparation of tetanus toxoid (TT) was used (Behring-Werke AG, Marburg, FRG; lot no. 831832, 2860 IU/mI) at a final concentration 0.1-1.0 IU/ml. AChR of Torpedo californica electric organ (Pacific Biomarine Lab., Venice, CA) was prepared as described (14) . Some preparations minced in the presence of enzyme inhibitors PMSF (Sigma Chemical Co., St. Louis, MO, IO-4 M) Iodoacetamide (Sigma Chemical Co., St.
Louis, MO, 5 X 103 M), EDTA (l0-3 M; Sigma Chemical Co.) in cold 50 mM phosphate buffer pH 7.4. After centrifugation (30,000 g, 30 min) the pellet was resuspended in 5 mM phosphate buffer pH 7.4 containing 2% Triton X-100 (Merck AG, Darmstadt, FRG) and extracted on a stirrer for 2 h. After a second centrifugation the supernatant that contained solubilized AChR was stored at -80°C or applied to a a-cobratoxin linked CNBr Sepharose column. After washing with buffer, AChR was competitively eluted with 0.2 M carbamylcholine (Sigma Chemical Co.) or 0.1 M hexamethoniumbromide (Fluka, Buchs, Switzerland). AChR was concentrated on a DEAE-A 25 column (Pharmacia Fine Chemicals, Freiburg, FRG) and eluted in a small volume by buffer containing 0.5 M NaCl. Before use in tissue culture, the detergent Triton X-100 had to be reduced by dialysis for 7 d in 5 mM phosphate buffer, pH 7.4. AChR had a specific activity of 4.8-8.0 nM a-bungarotoxin binding sites/mg protein as determined by a "II-a-bungarotoxin binding assay (16) . Concentration in tissue culture was I yg/ml (-4 X 10-9 M AChR).
HLA-typing. Typing of HLA-A, -B, -C as well as HLA-DR, -DQ antigen was done by the National Reference Laboratory (Prof. Dr. E. Albert, Munich, FRG) using standard typing material as defined by the 6th Workshop on Histocompatibility Testing 1984 (17) .
Isolation of PBMC. PBMC from EDTA blood were isolated by density centrifugation on Lymphoprep gradients (Nygaard, Oslo, Norway) for 30 min at 800 g. After being washed in Ca2"-Mg2' free PBS, 2 X 105 cells/well were cultured in 96 well microtiter plates (Nunc, Roskilde, Denmark) in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) plus 2% pooled human serum, 2 mM glutamine (Gibco), 100 U/ml penicillin and 100 Ag/ml streptomycin (Biochrom, Berlin, FRG) i.e., complete medium (CM) in the presence or absence of antigen or mitogen (TT 1.0 IU/ml, AChR 1 gg/ml, PHA-P 5 sg/ml). Cultures were incubated in 95% air, 5% CO2 for 5 d. We pulsed the cultures with 0.2 MCi ([3H]thymidine [3H]TdR, Amersham-Buchler, Braunschweig; specific activity 5 mCi/mM) for 16 h. before harvesting onto glass fiber filters by a Skatron Cell Harvester. Incorporated [3H]thymidine was measured by liquid scintillation counting in a beta-counter (Kontron, Basel, Switzerland).
Preparation ofthymocyte cell suspension. Thymus specimens were obtained at surgery and kept in cold Hepes buffered DME (Dulbecco's modified Eagle's medium; Gibco). Connective tissue of the fibrous capsule, septa and blood vessels were carefully removed. The trimmed thymus lobules were rinsed with DME to further minimize red blood cell contamination. Coarse mincing by scissors was followed by homogenization in a loosely fitting glass tissue homogenizer (Bellco, Vineland, NJ). The cell suspension was filtered through nylon wool to remove large particles. Aliquots ofthis single cell suspension were used for culture experiments, immunostaining, or were stored in liquid nitrogen. For tissue culture and staining experiments thymocytes could be fractionated on a discontinuous BSA gradient (Sigma Chemical Co.; density 1.081 g/ml) into low density (LD) and high density (HD) thymocytes. Most culture experiments were done with the LDfraction that appeared to be enriched for DR+ and surface Ig+ cells as compared to the original cell suspension (Table II) .
Thymocyte cultures. 3-4 X 105 LD-thymocytes were cultured in triplicates in CM (conditions see culture of PBMC) for 7-10 d without adding exogenous IL-2. Activated cells were separated by density gradient centrifugation and expanded in IL-2 containing growth medium (5-10 U/ml lymphocult HP; Biotest Diagnostics, Frankfurt, FRG). At 10-14-d intervals cells were restimulated with antigen presented by thawed autologous LD-thymocytes as described below.
Microproliferation assay. 2 X 104 antigen activated T lymphoblasts (from PBMC or thymus culture) were cultured in doublicates or triplicates with or without 2 X 105 irradiated (40 Gy) autologous PBMC or in the case ofthymus cultures 3-4 X 105 irradiated (40 Gy) autologous LD-thymocytes in 0.2 ml CM in the presence or absence of antigen or mitogen (see PBMC cultures). After 72 h cells were pulsed with [3H]-TdR and harvested 16 h later.
Analysis oflymphocyte populations with a FACS. Cytofluographic analysis ofcell populations was performed by means ofindirect immunofluorescence with fluoresceine conjugated F(ab)2 fragment of goat anti-mouse IgG (Medac, Hamburg, FRG; dilution 1:100) on an Ortho 30/50 system (Ortho, Neckargemund, FRG) using a linear scale.
Reagents Leu 3a, Leu 2a, anti-HLA-DR, anti-IL-2-receptor were purchased from Becton-Dickinson (Heidelberg, FRG), OKT 3, OKT 4, OKT 6, and OKT 8 were from Ortho, anti-human Ig-FITC was from Miles (Munich). All reagents were diluted 1:200. Background fluorescence activity (usually < 2%) was determined by incubation with the second antibody alone. This value was substracted from the individual results.
Immunohistochemistry. For a double marker analysis, combined staining with immunoperoxidase and alkaline phosphatase was applied to 5-Mm thick cryostat sections of fresh thymus tissue. The sections were fixed with acetone for 10 min at room temperature and air dried.
The monoclonal antibodies used were: (a) OKT 3, diluted 1:100; (b) KiM 1 (18), diluted 1:4000; (c) KiM 4 (19), diluted 1:5,000; (d) anti-desmin (Laboserv, Giessen, FRG), diluted 1:5. All antibodies were diluted with 0.1 M PBS, pH 7.4.
Demonstration of the first antigen was performed by the indirect immunoperoxidase technique using a three stage procedure, as described by Stein et al. (20) . After this reaction the immune staining of 
Results
Myasthenia patients. We analyzed peripheral blood lymphocytes and thymus cells from 10 MG patients who consecutively underwent transsternal thymectomy for therapeutic reasons (Table I) . All were female. With one exception, their symptoms were present for < 2 yr with clinical severity corre-sponding to Osserman classification type II A or II B. No previous immunosuppression had been given. The thymus of these patients showed typical lymphofollicular hyperplasia. In contrast to all other patients, patient D. E. was found to have a benign thymoma. This patient had been treated transiently with azathioprine. Disease duration was 20 yr.
The HLA phenotype was determined serologically in 10 patients. 6 ,ymphofollicular hyperplasia is thought to be linked to Significant reactions were seen in three of nine patient cultures enhanced disease susceptibility (22) . None of our pa-only. ?is demonstrated to be homnozygous in the DR region.
The pattern of antigen reactivity in primary thymus cell ciation ofmyoid cells, dendritic cells and T3' lymphocultures did not principally differ from the one in PBL culthymus medulla. All thymuses with lymphofollicular tures. Two features appear, however, worth mentioning. First asia showed marked expansion of the perivascular of all, like PBL cultures, most primary thymus cultures rid marked "peripheralization" of the medullary areas.
showed reactivity against TT (7/8). There was, however, a al centers were frequent and surrounded by T lym-relative increase of the primary AChR reactivity as compared areas of peripheral phenotype. A hallmark of all MG to the PBL cultures. 9 of 10 thymuses contained cells that r~s was the intimate association of myoid cells with reacted primarily against AChR, and, remarkably, the amplind their localization in areas occupied by "mature" tude of AChR reactions in some cases approached or even rmic lymphocytes. In contrast, myoid cells were never surpassed the one against TT, which was in striking contrast to germinal centers. (Fig. 1 ). Thymic tissue from non-MG the very low AChR reactivity in PBL cultures. Second, in obtained by heart surgery (seven cases) or autopsy thymus cultures more often than in PBL cultures, T cell prolifases) also contained myoid cells, but they were only eration was observed in the absence of any added exogenous -ely associated with IDCs (23).
(auto-)antigen. wary antigen reactivity ofperipheral blood and thymic T lymphocyte lines specific for AChR or TTfrom myascytes. Lymphocyte suspensions (PBL) were prepared thenic thymus and peripheral blood. After confrontation with .-ripheral blood samples and, in parallel, from speci-either AChR or TT in primary cultures activated T lympho-F freshly excised thymus tissue (Fig. 2 ). Specific reactiv-blasts were isolated by density gradient centrifugation, culnist AChR and against TT was assessed in vitro in pri-tured in the presence of IL-2 containing media, and were then ticrocultures. With the exception of three patients (J.S., again restimulated with antigen presented by autologous anti- selected from 8 of 10 mnyasthenic thymuses (Fig. 3 ). Further-LIII]~m ore, AChR specific T lines could be derived not only from TT~~f reshly processed thymus samples but from frozen samples as A~~hR~w ell. All these cell populations were strongly reactive against the AChR, but had lost their reactivity to TT. Reactivity against accessory cells alone, independent of the presentation of AChR (i.e., self-mixed lymphocyte reaction) varied between individual T lines. TT specific T cell lines were successfully selected from 7 of 8 thymus specimens (data not shown). They were highly reactive against the selecting antigen, TT, but ignored AChR. SMLC activity was seen in three of these cul- 
Discussion
This report demonstrates AChR reactive T lymphocytes in thymic tissues obtained from a series of 10 thymectomies of MG patients presenting successively at our clinic. Primary T cell stimulation was corroborated by the establishment of AChR specific T lines from 8/10 cases. We thus show that myasthenic thymuses regularly harbor significant numbers of autoreactive T lymphocytes specific for AChR. Which stimulus could activate and expand the intrathymic AChR specific T cell clones? The most plausible possibility is AChR produced locally and presented in an immunogenic way. AChR is synthesized in rich amounts by intrathymic seem to be in an activated state (37) and can be shown to DO synthesize autoantibodies against AChR (38, 39) , and permanent AChR specific B cell lines have been derived from MG thymuses (40) . One ble antigen can enter the medulla and be immunogenically presented by local presenter cells (44) . Indeed, in our series of myasthenic thymuses, besides AChR reactive T cells we also aid cells, which can also be induced in vitro to develop demonstrated T lymphocytes reacting against TT as a control iprimitive precursor cells (24, 25) . As any antigen to be (foreign) antigen. It is thus open, whether TT specific T cells gnized by T cells, AChR has to be taken up, processed and count among those T lymphocytes that have immigrated to pressed in the context of MHC antigens on the mem-the thymus after encountering their antigen in the periphery. es by "professional" antigen presenting cells (26) . The In principle, the AChR specific T cells demonstrated in our nic medulla contains high numbers of such presenting study may well be secondary immigrants as well rather than , e.g., IDCs (27, 28) . Three observations are in support of the direct progeny of intrathymically differentiating precursor cells. It should, however, be noted that the tissue distribution of AChR and TT specific T cells differed quite markedly. TT specific T cells could be isolated from peripheral blood of immune donors almost unfailingly. Within MG thymuses they were also demonstrable, but seemed to be somewhat less frequent than among peripheral blood lymphocytes. In contrast, the establishment of AChR specific T lines from peripheral blood lymphocytes, in agreement with other workers (45) , was difficult. AChR specific T lines were, however, regularly isolated from the thymus tissues from the same myasthenic patients of our series. Taken together, these data provide circumstantial evidence for a relative enrichment of AChR specific T cells within the myasthenic thymus, which could reflect either local expansion of peripheral, immigrant AChR specific T cells, or primary reactions of AChR specific T cells newly formed within the thymus.
Most of the thymuses in our series showed lympho-follicular hyperplasia and were derived from patients within the first two years of symptoms. An interesting exception was patient DE, who suffered from myasthenia for 20 years, was intermittently treated with azathioprine, and was found to have a benign thymoma. As reported in other studies (2, 46) , the neoplastic tissue portion was joined by residual thymus tissue with lympho-follicular hyperplasia and marked germinal center formation and preponderant mature T3' lymphocytes. Almost all of the thymomatous thymocytes had the immature, "cortical" T6' phenotype, as described in other thymomas (47) . Judging from their mature T3', T6phenotype, the AChR specific T cells should have been derived from the perithymomatous thymus residuum rather than from the tumor tissue. It will be ofinterest to determine, whether this is true for other cases of thymic neoplasia and myasthenia.
What is the functional role of thymic AChR specific T cells? First, no doubt, the pathogenesis of MG is based on anti-AChR autoantibodies which interfere with functional postsynaptic AChR (48) . Direct T cellular immune effector mechanisms have not been proven so far. Most, if not all pathogenic autoantibodies have y-isotypes (49), thus their synthesis depends on interactions of T-helper with B cells. All our thymus-derived T lines expressed the CD 4, "T-helper" membrane phenotype. They thus were analogous to T lines isolated from MG peripheral blood by ourselves and by others (45) . Indeed, Hohlfeld et al. showed that antigen recognition by blood-derived AChR specific T lines was restricted by HLA class II determinants (50) and that these cells were able to enhance in vitro production of anti AChR immunoglobulins by autologous blood B lymphocytes (51) . Although these observations do not prove that all AChR specific T cells are indeed involved in the production ofpathogenic autoantibodies, it seems reasonable to assume that the AChR specific T lines contain at least some T helper cells indirectly involved in the pathogenesis of MG. Our finding that the thymus apparently contains impressive numbers of such cells is compatible with an active role of the thymus in MG pathogenesis. It remains to be established whether the thymus indeed is the primary site of the myasthenogenic anti-AChR T cell reaction, as postulated by us before, or whether it acts as an amplifier or a depot of pathogenic T helper cells. In either case, however, thymectomy at an early stage of disease would be justified as a radical and rational therapy.
